

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (ZZ-101) TOVETUMAB

PRONUNCIATION toe vet' ue mab

THERAPEUTIC CLAIM Treatment of cancer

## CHEMICAL NAMES

1. Immunoglobulin G2, anti-(human platelet-derived growth factor receptor  $\alpha$ ) (human monoclonal MEDI-575 heavy chain), disulfide with human monoclonal MEDI-575  $\kappa$ -chain, dimer
2. Immunoglobulin G2, anti-(human platelet-derived growth factor receptor alpha (CD140a antigen)); human monoclonal MEDI-575  $\gamma$ 2 heavy chain (134-215)-disulfide with human monoclonal MEDI-575  $\kappa$  light chain dimer (222-222":223-223":226-226":229-229")-tetrakisdisulfide

## STRUCTURAL FORMULA

## Heavy chain

QVQLVESGGG	LVKPGGSLRL	SCAASGFTFS	DYYMNWIRQA	PGKLEWVSY	50
ISSSGSIYY	ADSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCAREG	100
RIAARGMDVW	GQTTTIVVSS	ASTKGPSVFP	LAPCSRSTSE	STAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSNFGTQT	200
YTCNVDHKPS	NTKVDKTVER	KCCVECPPCP	APPVAGPSVF	LFPPKPKDTL	250
MISRTPEVTC	VVVDVSHEDP	EVQFNWYVDG	VEVHNAKTKP	REEQFNSTFR	300
VVSVLTVVHQ	DWLNGKEYKC	KVSNKGLPAP	IEKTI SKTKG	QPREPOVYTL	350
PPSREEMTKN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	KTTTPMLDSD	400
GSFFLYSKLT	VDKSRWQQGN	VFSCSVMHEA	LHNHYTQKSL	SLSPGK	446

## Light chain

DIQMTQSPSS	LSASVGDVRS	ITCRPSQSFS	RYINWYQQKP	GKAPKLLIHA	50'
ASSLVGGVPS	RFSGSGSGTD	FTLTISLQP	EDFATYYCQQ	TYSNPPITFG	100'
QGTRLEMKRT	VAAPSVFIFP	PSDEQLKSGT	ASVCLLNNF	YPREAKVQWK	150'
VDNALQSGNS	QESVTEQDSK	DSTYLSSTL	TLSKADYEKH	KVYACEVTHQ	200'
GLSSPVTKSF	NRGEC				215'

## Disulfide bridges

22-96	22"-96"	23'-88'	23"-88"	134-215'	134"-215"
135'-195'	135"-195"	147-203	147"-203"	222-222"	223-223"
226-226"	229-229"	260-320	260"-320"	366-424	366"-424"

## Glycosylation sites (N)

Asn-296 Asn-296'

MOLECULAR FORMULA  $C_{6400}H_{9906}N_{1726}O_{2002}S_{54}$ 

MOLECULAR WEIGHT 144.8 kDa (peptide)

TRADEMARK None as yet

SPONSOR MedImmune, LLC

CODE DESIGNATIONS MEDI-575

CAS REGISTRY NUMBER 1243266-04-7

WHO NUMBER

9778

gbk